Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Androgen-Resistant Prostatic Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04689828
What this trial is testing

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Novartis Pharmaceuticals 469
Testing effectiveness (Phase 2)Active Not RecruitingNCT04090528
What this trial is testing

PTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Who this might be right for
Castration-resistant Prostate CancerMetastatic CancerProstate Cancer
University of Wisconsin, Madison 60
Not applicableUnknownNCT00967954
What this trial is testing

Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer

Who this might be right for
Prostate Cancer
Cancer Research UK 120
Testing effectiveness (Phase 2)Looking for participantsNCT07142551
What this trial is testing

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 60
Early research (Phase 1)Study completedNCT03551782
What this trial is testing

Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostatic Neoplasms
Janssen Research & Development, LLC 33
Testing effectiveness (Phase 2)Ended earlyNCT01420861
What this trial is testing

GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
GTx 18
Testing effectiveness (Phase 2)UnknownNCT02049190
What this trial is testing

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Prostate CancerAndrogen-independent Prostate Cancer+1 more
Arno Therapeutics 75
Testing effectiveness (Phase 2)Looking for participantsNCT07226986
What this trial is testing

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Who this might be right for
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals 123
Testing effectiveness (Phase 2)Study completedNCT00448409
What this trial is testing

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

Who this might be right for
Prostatic Neoplasms
The Methodist Hospital Research Institute 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT07047118
What this trial is testing

JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals 138
Testing effectiveness (Phase 2)Looking for participantsNCT06059118
What this trial is testing

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 50
Testing effectiveness (Phase 2)Looking for participantsNCT07832292
What this trial is testing

JNJ-101556143 in Participants With Metastatic Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 100
Not applicableLooking for participantsNCT07463092
What this trial is testing

Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy

Who this might be right for
Prostate CancerSarcopenia
University of Sao Paulo 34
Testing effectiveness (Phase 2)Looking for participantsNCT07206056
What this trial is testing

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Who this might be right for
Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals 188
Large-scale testing (Phase 3)Study completedNCT01006395
What this trial is testing

Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)

Who this might be right for
Prostate Cancer
Austin Health 64
Testing effectiveness (Phase 2)Study completedNCT01393730
What this trial is testing

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Mary-Ellen Taplin, MD 40
Not applicableStudy completedNCT00853164
What this trial is testing

A Pilot Study of Physical Activity for Improving Quality of Life in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Who this might be right for
Prostate Cancer
Washington University School of Medicine 8
Not applicableNot Yet RecruitingNCT07064811
What this trial is testing

Standardized Resistance Training Program and Assessment System for Prostate Cancer Patients Receiving Androgen Deprivation Therapy ISPoRT-PCa-ADT Study Protocol for a Randomized Controlled Trial. SPORT-MU

Who this might be right for
Prostate Cancer
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia 60
Testing effectiveness (Phase 2)Study completedNCT00096499
What this trial is testing

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

Who this might be right for
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Study completedNCT00901342
What this trial is testing

Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Dendreon 104
Next Page